| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Cancer Immunobiology Center [T. F., S. M., T. T., N. L., J. U.] and Departments of Urology, Surgery, Pathology, and Oncology [A. S., E. C., P. B., H. S., D. E.], University of Texas Southwestern Medical Center, Dallas, Texas 75390; Vysis, Inc., Downers Grove, Illinois 60515 [L. M.]; National Cancer Institute, Bethesda, Maryland 20892 [B. M. G., K. H-H., T. R.]; and Immunicon Corporation, Huntingdon, Pennsylvania 19006 [C. R.]
Purpose: Numerous studies of circulating epithelial cells (CECs)have been described in cancer patients, and genetic abnormalities have been well documented. However, with one exception in colorectal cancer, there has been no report of matching the genetic abnormalities in the CECs with the primary tumor. The purpose of this investigation was to determine (a) whether CECs in patients including those with early tumors are aneusomic and (b) whether their aneusomic patterns match those from the primary tumor, indicating common clonality.
Experimental Design: Thirty-one cancer patients had CECs identified by immunofluorescence staining using a monoclonal anti-cytokeratin antibody. Their CECs were analyzed by enumerator DNA probes for chromosomes 1, 3, 4, 7, 8, 11, or 17 by dual or tricolor fluorescence in situ hybridization. Touch preparations of the primary tumor tissue were available from 17 of 31 patients and hybridized with the same set of probes used to genotype the CECs.
Results: The number of CECs from each patient ranged from 1–92 cells/cytospin. CECs showed abnormal copy numbers for at least one of the probes in 25 of 31 patients. Touch preparations from the primary tumors of 13 patients with aneusomic CECs were available. The pattern of aneusomy matched a clone in the primary tumor in 10 patients.
Conclusions: We conclude that the vast majority of CECs in breast, kidney, prostate, and colon cancer patients are aneusomic and derived from the primary tumor.
This article has been cited by other articles:
|
|
 |
|
  C. P. Carden, D. Olmos, and J. S. de Bono Validated and Qualified Biomarkers Are Critical to Optimizing Anticancer Drug Development: Potential Roles for the Study of Circulating Tumor Cells ASCO Educational Book, January 1, 2008; 2008(1): 166 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. de Bono, G. Attard, A. Adjei, M. N. Pollak, P. C. Fong, P. Haluska, L. Roberts, C. Melvin, M. Repollet, D. Chianese, et al. Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor Clin. Cancer Res., June 15, 2007; 13(12): 3611 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. U. Bai, A. Kaseb, S. Tejwani, G. W. Divine, E. R. Barrack, M. Menon, A. B. Pardee, and G. P.-V. Reddy Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine PNAS, February 13, 2007; 104(7): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meng, D. Tripathy, S. Shete, R. Ashfaq, H. Saboorian, B. Haley, E. Frenkel, D. Euhus, M. Leitch, C. Osborne, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues PNAS, November 14, 2006; 103(46): 17361 - 17365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Braun, F. D. Vogl, B. Naume, W. Janni, M. P. Osborne, R. C. Coombes, G. Schlimok, I. J. Diel, B. Gerber, G. Gebauer, et al. A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer N. Engl. J. Med., August 25, 2005; 353(8): 793 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Braun and B. Naume Circulating and Disseminated Tumor Cells J. Clin. Oncol., March 10, 2005; 23(8): 1623 - 1626. [Full Text] [PDF]
|
|
|
|
|
|
M. Cristofanilli, D. F. Hayes, G. T. Budd, M. J. Ellis, A. Stopeck, J. M. Reuben, G. V. Doyle, J. Matera, W. J. Allard, M. C. Miller, et al. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1420 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy Clin. Cancer Res., December 15, 2004; 10(24): 8152 - 8162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiegl, H. Denz, I. H. Kunkler, C. Tang, A. Y. Lin, A. C. Voogd, K. van Gestel, M. F. Ernst, M. Cristofanilli, L. W.M.M. Terstappen, et al. Circulating Epithelial Cells in Breast Cancer N. Engl. J. Med., December 2, 2004; 351(23): 2452 - 2454. [Full Text] [PDF]
|
|
|
|
|
|
W. J. Allard, J. Matera, M. C. Miller, M. Repollet, M. C. Connelly, C. Rao, A. G. J. Tibbe, J. W. Uhr, and L. W. M. M. Terstappen Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases Clin. Cancer Res., October 15, 2004; 10(20): 6897 - 6904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cristofanilli, G. T. Budd, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller, J. M. Reuben, G. V. Doyle, W. J. Allard, L. W.M.M. Terstappen, et al. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer N. Engl. J. Med., August 19, 2004; 351(8): 781 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Meng, D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, A. Khan, D. Euhus, C. Osborne, et al. HER-2 gene amplification can be acquired as breast cancer progresses PNAS, June 22, 2004; 101(25): 9393 - 9398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiegl, M. Haun, A. Massoner, J. Krugmann, E. Muller-Holzner, R. Hack, W. Hilbe, C. Marth, H.-C. Duba, G. Gastl, et al. Combination of Cytology, Fluorescence In Situ Hybridization for Aneuploidy, and Reverse-Transcriptase Polymerase Chain Reaction for Human Mammaglobin/Mammaglobin B Expression Improves Diagnosis of Malignant Effusions J. Clin. Oncol., February 1, 2004; 22(3): 474 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer Clin. Cancer Res., December 15, 2003; 9(17): 6326 - 6334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes Cancer Res., August 1, 2003; 63(15): 4662 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiegl, B. Kircher, and N. Zojer Correspondence re: T. Fehm et al., Cytogenetic Evidence that Circulating Epithelial Cells in Patients with Carcinoma Are Malignant. Clin. Cancer Res., 8: 2073-2084, 2002. Clin. Cancer Res., March 1, 2003; 9(3): 1224 - 1225. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
